(NASDAQ: NKTX) Nkarta's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Nkarta's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NKTX's revenue for 2028 to be $2,826,775,578, with the lowest NKTX revenue forecast at $2,826,775,578, and the highest NKTX revenue forecast at $2,826,775,578. On average, 1 Wall Street analysts forecast NKTX's revenue for 2029 to be $7,897,925,734, with the lowest NKTX revenue forecast at $7,897,925,734, and the highest NKTX revenue forecast at $7,897,925,734.
In 2030, NKTX is forecast to generate $7,608,358,799 in revenue, with the lowest revenue forecast at $1,186,109,350 and the highest revenue forecast at $13,253,173,939.